The standard management of high-grade upper tract urothelial carcinoma is radical nephroureterectomy. Nephron sparing approaches can be utilized for low-grade upper tract urothelial cancer and other highly selected cases. Ureteroscopy and percutaneous ablation and resection are effective for the initial treatment of non-invasive low-grade cancers. For selected patients this nephron sparing approach has had five-year cancer specific survival comparable to nephroureterectomy. Instillation of chemotherapy has been used for upper tract urothelial carcinoma but has not been previously well studied for primary treatment of these cancers. Temperature sensitive water soluble Mitomycin proprietary agent has recently been developed that has been effective for the primary treatment of upper tract low-grade urothelial carcinoma.
This webinar (followed by a live Q&A) will review indications for radical nephroureterectomy versus endoscopic ablation versus intracavitary Mitomycin gel therapy. There will be practical management strategies, tips and case-based discussion by expert faculty. It will be most useful for urologists and other physicians managing upper tract urothelial cancers.